Estrogen-Progestogen Therapy at Age 75: Fracture Risk Reduction
Starting estrogen-progestogen therapy at age 75 would reduce total fracture risk by approximately 24% (relative risk reduction), but this therapy is NOT recommended at this age due to serious harms that substantially outweigh the fracture benefits.
Quantified Fracture Benefits
Based on the Women's Health Initiative data, estrogen plus progestin therapy demonstrates:
- Total fractures: 24% reduction (RH 0.76,95% CI 0.63-0.92) 1222
- Hip fractures: 34% reduction (RH 0.66, though not statistically significant in adjusted analyses) 222
- Vertebral fractures: 34% reduction (RH 0.66, not statistically significant) 222
In absolute terms, for every 10,000 women treated for one year, there would be 46 fewer fractures 1.
A meta-analysis of 22 trials showed a 27% reduction in nonvertebral fractures (RR 0.73,95% CI 0.56-0.94) 222.
Critical Age-Related Considerations
The fracture benefit does NOT differ by age - the 24% reduction applies equally to women over 75 3. However, this is precisely why the recommendation against use is so important: the harms accumulate while the absolute benefit remains modest.
Why This Is NOT Recommended at Age 75
For every 10,000 women aged 50-79 (average age 63) treated for one year, the therapy causes 1:
- 9 additional strokes
- 12 additional deep venous thromboses
- 9 additional pulmonary emboli
- 8 additional invasive breast cancers
- 22 additional cases of dementia
- 5 additional lung cancer deaths
At age 75, stroke and thromboembolic risks are substantially higher than at younger ages, making the harm-benefit ratio even more unfavorable 12.
The Timing Paradox
The evidence reveals a critical timing issue: Current use of estrogen is protective, but the protection requires continuous use 4. Women who started estrogen within 5 years of menopause and continued had a 71% reduction in hip fractures (RR 0.29), but previous use of estrogen for more than 10 years had no substantial effect if discontinued 4.
Starting at age 75 means initiating therapy 20-25 years after menopause - well outside the window where the benefit-risk profile is favorable.
Guideline Position
The USPSTF explicitly recommends AGAINST using estrogen-progestogen therapy for chronic disease prevention in postmenopausal women 2. This recommendation is based on the conclusion that harmful effects are likely to exceed chronic disease prevention benefits in most women 2.
The only FDA-approved indications are:
- Short-term treatment of menopausal symptoms
- Prevention of osteoporosis (but NOT as first-line in older women) 1
Alternative Approach for a 75-Year-Old
For osteoporosis management at age 75, evidence-based alternatives include:
- Bisphosphonates (first-line)
- Denosumab
- Raloxifene (reduces vertebral fractures by 30% with better safety profile) 5
- Anabolic agents (teriparatide, abaloparatide, romosozumab) for high-risk patients 67
These agents provide fracture protection without the cardiovascular, thromboembolic, and cognitive risks associated with hormone therapy in older women.
Common Pitfall to Avoid
Do not confuse the fracture efficacy data with a recommendation to use this therapy at age 75. While the 24% fracture reduction is real and statistically significant, the global index showed no net benefit even in women at high risk of fracture when all health outcomes were considered 3. The harm-benefit calculation becomes progressively worse with advancing age due to increased baseline cardiovascular and thromboembolic risk.